TKD Balance Sheet - Takeda Pharmaceutical Co Ltd

Watchlist Manager

Watchlist

Price: 37.58 EUR 1.4% Market Closed

Market Cap: €59.8B

Financial profile · Q2 FY2027

A global pharmaceutical platform with durable cash generation and uneven reported earnings

Takeda's multi-year record combines a broad revenue base with operating earnings that vary as intangible-asset amortization, impairments and restructuring shift. It generates substantial operating cash, while meaningful capital spending reduces the amount converted into free cash flow.

What is developing

The latest quarter showed positive reported earnings and a stronger operating margin, but trailing operating income remains subdued and first-half reported revenue growth was largely currency-driven. This is an improvement in reported results, not clear evidence of a changed underlying growth or margin profile.

What matters next

Whether constant-currency revenue growth turns positive while trailing operating income continues to recover.

Metric	FY2017 Mar 2017	FY2018 Mar 2018	FY2019 Mar 2019	FY2020 Mar 2020	FY2021 Mar 2021	FY2022 Mar 2022	FY2023 Mar 2023	FY2024 Mar 2024	FY2025 Mar 2025	FY2026 Mar 2026
Cash & Cash Equivalents	278.5B	243.3B	462.9B	188.6B	335B	389.1B	229.6B	457.8B	385.1B	595.1B
Cash Equivalents	278.5B	243.3B	462.9B	188.6B	335B	389.1B	229.6B	457.8B	385.1B	595.1B
Short-Term Investments	97.7B	131.9B	262.9B	464.8B	667.8B	485.9B	324.1B	267.7B	171.8B	492.2B
Total Receivables	444.8B	428.8B	749.1B	784.9B	812.7B	724.4B	681.7B	697.6B	725.3B	876.3B
Accounts Receivables	356.5B	360.8B	657.7B	670.7B	707.5B	617.5B	575.4B	612.4B	651.4B	808B
Other Receivables	88.3B	68B	91.4B	114.2B	105.2B	106.9B	106.3B	85.2B	73.8B	68.3B
Inventory	226B	212.9B	919.7B	759.6B	753.9B	853.2B	986.5B	1.2T	1.2T	1.4T
Other Current Assets	213.5B	61.9B	598.4B	271.5B	143.5B	141.1B	176.1B	178.2B	173B	180.6B
Total Current Assets	1.3T	1.1T	3T	2.5T	2.7T	2.6T	2.4T	2.6T	2.5T	3.1T
PP&E Net	527.3B	536.8B	1.3T	1.4T	1.5T	1.6T	1.7T	2T	2T	2.1T
PP&E Gross	527.3B	536.8B	1.3T	1.4T	1.5T	1.6T	1.7T	2T	2T	2.1T
Accumulated Depreciation	(607.1B)	(654.6B)	(639.6B)	(697.8B)	(737.8B)	(870.2B)	(1T)	(1.2T)	(1.3T)	(1.5T)
Intangible Assets	1.1T	1T	4.8T	4.2T	3.9T	3.8T	4.3T	4.3T	3.6T	3.4T
Goodwill	1T	1T	4.2T	4T	4T	4.4T	4.8T	5.4T	5.3T	5.8T
Long-Term Investments	303B	304.4B	299.9B	369.5B	348.4B	330.1B	378.9B	430.6B	361.9B	448.7B
Other Long-Term Assets	173.4B	143B	176.5B	411.9B	454.1B	445.2B	429.3B	445.1B	441B	623.3B
Other Assets	1T	1T	4.2T	4T	4T	4.4T	4.8T	5.4T	5.3T	5.8T
Total Assets	4.3T	4.1T	13.8T	12.8T	12.9T	13.2T	14T	15.1T	14.2T	15.5T
Accounts Payable	125.7B	133.7B	212.3B	211.6B	232.1B	295.9B	307.5B	320B	308.5B	324.4B
Short-Term Debt	405.1B	18m	500B	5B	69m	285m	256m	251m	74.6B	19m
Current Portion of Long-Term Debt	140B	—	484.9B	581.8B	22.1B	203.7B	339.3B	367B	474.3B	512.1B
Other Current Liabilities	695.6B	603.8B	1.4T	1.4T	1.5T	1.6T	1.8T	1.6T	1.6T	2T
Total Current Liabilities	1.4T	737.5B	2.6T	2.2T	1.8T	2.1T	2.5T	2.3T	2.5T	2.8T
Long-Term Debt	599.9B	985.6B	4.8T	4.5T	4.6T	4.1T	4T	4.5T	4T	4.4T
Deferred Income Tax	153.4B	90.7B	783.4B	765.1B	576.5B	473.1B	295.2B	118.2B	35.5B	26.8B
Minority Interest	54.7B	20B	4B	4B	4.1B	504m	549m	741m	895m	1.2B
Other Liabilities	278.2B	275.2B	504.4B	646.1B	772.2B	734.2B	783.2B	927B	804B	852.3B
Total Liabilities	2.5T	2.1T	8.6T	8.1T	7.7T	7.5T	7.6T	7.8T	7.3T	8.1T
Common Stock	65.2B	77.9B	1.6T	1.7T	1.7T	1.7T	1.7T	1.7T	1.7T	1.7T
Retained Earnings	1.5T	1.6T	1.6T	1.4T	1.5T	1.5T	1.5T	1.4T	1.2T	712.4B
Additional Paid In Capital	75B	90.7B	1.7T	1.7T	1.7T	1.7T	1.7T	1.7T	1.8T	1.8T
Unrealized Security Profit/Loss	68B	73B	46.4B	22.9B	42B	22.1B	12.5B	15.7B	4.8B	12B
Treasury Stock	(48.7B)	(74.4B)	(57.1B)	(87.5B)	(59.6B)	(116B)	(100.3B)	(51.3B)	(74.8B)	(49.1B)
Other Equity	223B	272.8B	303.5B	69.7B	324.1B	912.1B	1.5T	2.5T	2.3T	3.3T
Total Equity	1.9T	2T	5.2T	4.7T	5.2T	5.7T	6.4T	7.3T	6.9T	7.4T
Total Liabilities & Equity	4.3T	4.1T	13.8T	12.8T	12.9T	13.2T	14T	15.1T	14.2T	15.5T
Common Shares Outstanding	780.8m	781.3m	1.6B	1.6B	1.6B	1.6B	1.6B	1.6B	1.6B	1.6B